Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo

Charles L. Bowden, Michelle A. Collins, Susan L. McElroy, Joseph R. Calabrese, Alan C. Swann, Richard H. Weisler, Patricia J. Wozniak

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Euphoric and mixed (dysphoric) manic symptoms have different response patterns to divalproex and lithium in acute mania treatment, but have not been studied in relationship to maintenance treatment outcomes. We examined the impact of initial euphoric or dysphoric manic symptomatology on maintenance outcome. Randomized maintenance treatment with divalproex, lithium, or placebo was provided for 372 bipolar I patients, who met improvement criteria during open phase treatment for an index manic episode. The current analysis grouped patients according to the index manic episode subtype (euphoric or dysphoric), and evaluated the impact on maintenance treatment outcome. The rate of early discontinuation due to intolerance during maintenance treatment was higher for initially dysphoric patients (N=249) than euphoric patients (N=123; 15.7 vs 7.3%, respectively; p=0.032). Both lithium (23.2%) and divalproex (17.1%) were associated with more premature discontinuations due to intolerance than placebo (4.8%; p=0.003 and 0.02, respectively) in the initially dysphoric patients. Among initially euphoric patients, treatment with lithium was associated with significantly more premature discontinuations due to intolerance compared to placebo (18.2 vs 0%; p=0.03), and divalproex was significantly (p=0.05) more effective than lithium, but not placebo in delaying time to a depressive episode. Initial euphoric mania appeared to predispose to better outcomes on indices of depression and overall function with divalproex maintenance than with either placebo or lithium. Dysphoric mania appeared to predispose patients to more side effects when treated with either divalproex or lithium during maintenance therapy.

Original languageEnglish (US)
Pages (from-to)1932-1939
Number of pages8
JournalNeuropsychopharmacology
Volume30
Issue number10
DOIs
StatePublished - Oct 2005

Fingerprint

Valproic Acid
Bipolar Disorder
Lithium
Placebos
Therapeutics
Maintenance
Depression

Keywords

  • Bipolar disorder
  • Divalproex
  • Dysphoric
  • Euphoric
  • Lithium
  • Maintenance

ASJC Scopus subject areas

  • Pharmacology

Cite this

Bowden, C. L., Collins, M. A., McElroy, S. L., Calabrese, J. R., Swann, A. C., Weisler, R. H., & Wozniak, P. J. (2005). Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo. Neuropsychopharmacology, 30(10), 1932-1939. https://doi.org/10.1038/sj.npp.1300788

Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo. / Bowden, Charles L.; Collins, Michelle A.; McElroy, Susan L.; Calabrese, Joseph R.; Swann, Alan C.; Weisler, Richard H.; Wozniak, Patricia J.

In: Neuropsychopharmacology, Vol. 30, No. 10, 10.2005, p. 1932-1939.

Research output: Contribution to journalArticle

Bowden, CL, Collins, MA, McElroy, SL, Calabrese, JR, Swann, AC, Weisler, RH & Wozniak, PJ 2005, 'Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo', Neuropsychopharmacology, vol. 30, no. 10, pp. 1932-1939. https://doi.org/10.1038/sj.npp.1300788
Bowden, Charles L. ; Collins, Michelle A. ; McElroy, Susan L. ; Calabrese, Joseph R. ; Swann, Alan C. ; Weisler, Richard H. ; Wozniak, Patricia J. / Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo. In: Neuropsychopharmacology. 2005 ; Vol. 30, No. 10. pp. 1932-1939.
@article{6b47f044ed9d49d4aa069aa6f3944d6f,
title = "Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo",
abstract = "Euphoric and mixed (dysphoric) manic symptoms have different response patterns to divalproex and lithium in acute mania treatment, but have not been studied in relationship to maintenance treatment outcomes. We examined the impact of initial euphoric or dysphoric manic symptomatology on maintenance outcome. Randomized maintenance treatment with divalproex, lithium, or placebo was provided for 372 bipolar I patients, who met improvement criteria during open phase treatment for an index manic episode. The current analysis grouped patients according to the index manic episode subtype (euphoric or dysphoric), and evaluated the impact on maintenance treatment outcome. The rate of early discontinuation due to intolerance during maintenance treatment was higher for initially dysphoric patients (N=249) than euphoric patients (N=123; 15.7 vs 7.3{\%}, respectively; p=0.032). Both lithium (23.2{\%}) and divalproex (17.1{\%}) were associated with more premature discontinuations due to intolerance than placebo (4.8{\%}; p=0.003 and 0.02, respectively) in the initially dysphoric patients. Among initially euphoric patients, treatment with lithium was associated with significantly more premature discontinuations due to intolerance compared to placebo (18.2 vs 0{\%}; p=0.03), and divalproex was significantly (p=0.05) more effective than lithium, but not placebo in delaying time to a depressive episode. Initial euphoric mania appeared to predispose to better outcomes on indices of depression and overall function with divalproex maintenance than with either placebo or lithium. Dysphoric mania appeared to predispose patients to more side effects when treated with either divalproex or lithium during maintenance therapy.",
keywords = "Bipolar disorder, Divalproex, Dysphoric, Euphoric, Lithium, Maintenance",
author = "Bowden, {Charles L.} and Collins, {Michelle A.} and McElroy, {Susan L.} and Calabrese, {Joseph R.} and Swann, {Alan C.} and Weisler, {Richard H.} and Wozniak, {Patricia J.}",
year = "2005",
month = "10",
doi = "10.1038/sj.npp.1300788",
language = "English (US)",
volume = "30",
pages = "1932--1939",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo

AU - Bowden, Charles L.

AU - Collins, Michelle A.

AU - McElroy, Susan L.

AU - Calabrese, Joseph R.

AU - Swann, Alan C.

AU - Weisler, Richard H.

AU - Wozniak, Patricia J.

PY - 2005/10

Y1 - 2005/10

N2 - Euphoric and mixed (dysphoric) manic symptoms have different response patterns to divalproex and lithium in acute mania treatment, but have not been studied in relationship to maintenance treatment outcomes. We examined the impact of initial euphoric or dysphoric manic symptomatology on maintenance outcome. Randomized maintenance treatment with divalproex, lithium, or placebo was provided for 372 bipolar I patients, who met improvement criteria during open phase treatment for an index manic episode. The current analysis grouped patients according to the index manic episode subtype (euphoric or dysphoric), and evaluated the impact on maintenance treatment outcome. The rate of early discontinuation due to intolerance during maintenance treatment was higher for initially dysphoric patients (N=249) than euphoric patients (N=123; 15.7 vs 7.3%, respectively; p=0.032). Both lithium (23.2%) and divalproex (17.1%) were associated with more premature discontinuations due to intolerance than placebo (4.8%; p=0.003 and 0.02, respectively) in the initially dysphoric patients. Among initially euphoric patients, treatment with lithium was associated with significantly more premature discontinuations due to intolerance compared to placebo (18.2 vs 0%; p=0.03), and divalproex was significantly (p=0.05) more effective than lithium, but not placebo in delaying time to a depressive episode. Initial euphoric mania appeared to predispose to better outcomes on indices of depression and overall function with divalproex maintenance than with either placebo or lithium. Dysphoric mania appeared to predispose patients to more side effects when treated with either divalproex or lithium during maintenance therapy.

AB - Euphoric and mixed (dysphoric) manic symptoms have different response patterns to divalproex and lithium in acute mania treatment, but have not been studied in relationship to maintenance treatment outcomes. We examined the impact of initial euphoric or dysphoric manic symptomatology on maintenance outcome. Randomized maintenance treatment with divalproex, lithium, or placebo was provided for 372 bipolar I patients, who met improvement criteria during open phase treatment for an index manic episode. The current analysis grouped patients according to the index manic episode subtype (euphoric or dysphoric), and evaluated the impact on maintenance treatment outcome. The rate of early discontinuation due to intolerance during maintenance treatment was higher for initially dysphoric patients (N=249) than euphoric patients (N=123; 15.7 vs 7.3%, respectively; p=0.032). Both lithium (23.2%) and divalproex (17.1%) were associated with more premature discontinuations due to intolerance than placebo (4.8%; p=0.003 and 0.02, respectively) in the initially dysphoric patients. Among initially euphoric patients, treatment with lithium was associated with significantly more premature discontinuations due to intolerance compared to placebo (18.2 vs 0%; p=0.03), and divalproex was significantly (p=0.05) more effective than lithium, but not placebo in delaying time to a depressive episode. Initial euphoric mania appeared to predispose to better outcomes on indices of depression and overall function with divalproex maintenance than with either placebo or lithium. Dysphoric mania appeared to predispose patients to more side effects when treated with either divalproex or lithium during maintenance therapy.

KW - Bipolar disorder

KW - Divalproex

KW - Dysphoric

KW - Euphoric

KW - Lithium

KW - Maintenance

UR - http://www.scopus.com/inward/record.url?scp=27144520494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144520494&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1300788

DO - 10.1038/sj.npp.1300788

M3 - Article

VL - 30

SP - 1932

EP - 1939

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 10

ER -